Effect of low-dose of recombinant human growth hormone on bone metabolism in elderly women with osteoporosis

European Journal of Endocrinology

Volumn 147, Issue 3, 2002, Pages 339-348

  Sugimoto, Toshitsugu ^a   Kaji, Hiroshi ^a   Nakaoka, Daiki ^a   Yamauchi, Mika ^a   Yano, Shozo ^a   Sugishita, Takeshi ^a   Baylink, David J ^a   Mohan, Subburaman ^a   Chihara, Kazuo ^a  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; HUMAN GROWTH HORMONE; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

AGED; ARTHRALGIA; ARTICLE; ATTENUATION; BODY COMPOSITION; BONE DENSITY; BONE MASS; BONE METABOLISM; BONE MINERAL; BONE TURNOVER; CLINICAL ARTICLE; CONTROLLED STUDY; DIETARY INTAKE; DOSE RESPONSE; DRUG EFFECT; DRUG WITHDRAWAL; EDEMA; ELDERLY CARE; EXERCISE; FEMALE; FRACTURE; GRIP STRENGTH; HAND GRIP; HUMAN; JAPAN; LUMBAR SPINE; MEDICAL INFORMATION; MUSCLE STRENGTH; OSSIFICATION; OSTEOLYSIS; OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS; TREATMENT OUTCOME;

EID: 0036737929     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.0.1470339     Document Type: Article

References (46)

1. Corpas E, Harman SM & Blackman MR. Human growth hormone and human aging. Endocrine Review 1993 14 20-39.
2. Bing-You RG, Denis MC & Rosen CJ. Low bone mineral density in adults with previous hypothalamic-pituitary tumors: correlations with serum growth hormone response to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcified Tissue International 1993 52 183-187.
3. O'Halloran DJ, Tsatsoulis A, Whitehouse RW, Holmes SJ, Adams JE & Shalet SM. Increased bone density after recombinant human growth hormone (GH) therapy in adults with isolated GH deficiency. Journal of Clinical Endocrinology and Metabolism 1993 76 1344-1348.
4. Johansson AG, Forslund A, Hambraeus L, Blum WF & Ljunghall S. Growth hormone-dependent insulin-like growth factor binding protein is a major determinant of bone mineral density in healthy men. Journal of Bone and Mineral Research 1994 9 915-921.
5. Sugimoto T, Nishiyama K, Kuribayashi F & Chihara K. Serum levels of insulin-like growth factor (IGF)-I, IGF-binding protein (IGFBP)-2, and IGFBP-3 in osteoporotic patients with and without spinal fractures. Journal of Bone and Mineral Research 1997 12 1272-1279.
6. Rosen T, Hansson T, Cranhed H, Szuc J & Bengtsson BA. Reduced bone mineral content in adult patients with growth hormone deficiency. Acta Endocrinologica 1993 129 201-206.
7. Rosen T, Johannsson G, Hallgren P, Caidahl K, Bosaeus I & Bengtsson BA. Beneficial effects of 12 months replacement therapy with recombinant human growth hormone deficient adults. Endocrinology and Metabolism 1994 1 55-66.
8. Vandeweghe M, Taelman P & Kaufman JM. Short and long-term effects of growth hormone treatment on bone turnover and bone mineral content in adult growth hormone-deficient males. Clinical Endocrinology 1993 39 409-415.
9. Holmes SJ, Economou G, Whitehouse RW, Adams JE & Shalet SM. Reduced bone mineral density in patients with adult onset growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1994 78 669-674.
10. Wuster C, Abs R, Bengtsson BA, Bennmarker H, Deldt-Rasmussen U, Hernberg-Stahl E, Monson JP, Westberg B & Wilton P. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. Journal of Bone and Mineral Research 2001 16 398-405.
11. Vestergaard P, Jorgensen JO, Hagen C, Hoeck HC, Laurberg P, Rejnmark L, Brixen K, Weeke J, Andersen M, Conceicao FL, Nielsen TL & Mosekilde L. Fracture risk is increased in patients with GH deficiency or untreated prolactinomas - a case-control study. Clinical Endocrinology 2002 56 159-167.
12. Rudman D, Feller AG, Nagraj HS, Gergans GA, Lalitha PY, Goldberg AF, Schlenker RA, Cohn L, Rudman IW & Mattson DE. Effects of human growth hormone in men over 60 years old. New England Journal of Medicine 1990 323 1-6.
13. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT & Slootweg MC. Growth hormone and bone. Endocrine Reviews 1998 19 55-79.
14. Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T & Chihara K. Effect of recombinant human growth hormone in elderly osteoporotic women. Clinical Endocrinology 1999 51 715-724.
15. Rosen CJ, Donahue LR & Hunter SJ. Insulin-like growth factors and bone: the osteoporosis connection. Experimental Biology and Medicine 1994 206 83-102.
16. Feyen JH, Evans DB, Binkert C, Heinrich GF, Geisse S & Kocher HP. Recombinant human [Cys281] insulin-like growth factor-binding protein 2 inhibits both basal and insulin-like growth factor-I-stimulated proliferation and collagen synthesis in fetal rat calvariae. Journal of Biological Chemistry 1991 266 19469-19474.
17. Andress DL & Birnbaum RS. Human osteoblast-derived insulin-like growth factor (IGF) binding protein-5 stimulates osteoblast mitogenesis and potentiates IGF action. Journal of Biological Chemistry 1992 267 22467-22472.
18. Mohan S, Bautista C, Wergedal J & Baylink DJ. Isolation of an inhibitory insulin-like growth factor (IGF) binding protein from bone cell conditioned medium: a potential local regulator of IGF action. PNAS 1989 86 8338-8342.
19. Jones JI & Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocrine Reviews 1995 16 3-34.
20. Mohan S, Nakao Y, Honda Y, Landale E, Leser U, Dony C, Lang K & Baylink DJ. Studies on the mechanisms by which insulin-like growth factor (IGF) binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells. Journal of Biological Chemistry 1995 270 20424-20431.
21. Miyakoshi N, Richman C, Qin X, Baylink DJ & Mohan S. Effects of recombinant insulin-like growth factor-binding protein-4 on bone formation parameters in mice. Endocrinology 1999 140 5719-5728.
22. Andress DL & Birnbaum RS. A novel human insulin-like growth factor binding protein secreted by osteoblast-like cells. Biochemical and Biophysical Research Communications 1991 176 213-218.
23. Bautista CM, Baylink DJ & Mohan S. Isolation of a novel insulin-like growth factor (IGF) binding protein from human bone: a potential candidate for fixing IGF-II in human bone. Biochemical and Biophysical Research Communications 1991 176 756-763.
24. Minne HW, Leidig G, Wuster C, Siromachkostov L, Baldauf G, Bickel R, Sauer P, Lojen M & Ziegler R. A newly developed spine deformity index (SDI) to quantitate vertebral crush fractures in patients with osteoporosis. Bone and Mineral 1988 3 335-349.
25. Hummer L, Riis BJ, Christiansen C & Rickers H. Determination of mono- and dihydroxyvitamin D metabolites in normal subjects and patients with different calcium metabolic disease. Scandinavian Journal of Clinical Laboratory Investigation 1985 45 611-619.
26. Honda Y, Landale EC, Strong DD, Baylink DJ & Mohan S. Recombinant synthesis of insulin-like growth factor-binding protein-4 (IGFBP-4): development, validation and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids. Journal of Clinical Endocrinology and Metabolism 1996 81 1389-1396.
27. Mohan S, Libanati C, Dony C, Lang K, Srinivasan N & Baylink DJ. Development, validation and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids. Journal of Clinical Endocrinology and Metabolism 1995 80 2638-2645.
28. Valimaki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H & Soppi E. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. European Journal of Endocrinology 1999 140 545-554.
29. Johansson G, Rosen T, Bosaeus I, Sjostrom L & Bengtsson BA. Two years of growth hormone (GH) treatment increases bone mineral content and density in hypopituitary patients with adult-onset GH deficiency. Journal of Clinical Endocrinology and Metabolism 1996 81 2865-2873.
30. Holmes SJ, Whitehouse RW, Economou G, O'Halloran DJ, Adams JE & Shalet SM. Further increase in forearm cortical bone mineral content after discontinuation of growth hormone replacement. Clinical Endocrinology 1995 42 3-7.
31. Kassem M, Brixen K, Mosekilde L, Blum WF & Flyvbjerg A. Effects of growth hormone treatment on serum levels of insulin-like growth factors (IGFs) and IGF-binding proteins 1-4 in postmenopausal women. Clinical Endocrinology 1998 49 747-756.
32. Dall R, Longobardi S, Ehrnborg C, Keay N, Rosen T, Jorgensen JO, Cuneo RC, Boroujerdi MA, Cittadini A, Napoli R, Christiansen JS, Bengtsson BA, Sacca L, Baxter RC, Basset EE & Sonksen PH. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. Journal of Clinical Endocrinology and Metabolism 2000 85 4193-4200.
33. Rosen C, Donahue LR, Hunter S, Holick M, Kavookjian H, Kirschenbaum A, Mohan S & Baylink DJ. The 24/25-kDa serum insulin-like growth factor-binding protein is increased in elderly women with hip and spine fractures. Journal of Clinical Endocrinology and Metabolism 1992 74 24-27.
34. Amarnani S, Merriman HL, Linkhart TA, Baylink DJ & Mohan S. Autocrine regulators of MC3T3-E1 cell proliferation. Journal of Bone and Mineral Research 1993 8 157-165.
35. Scharla SH, Strong DD, Mohan S, Baylink DJ & Linkhart TA. 1,25-Dihydroxyvitamin D3 differentially regulates the production of insulin-like growth factor I (IGF-I) and IGF-binding protein-4 in mouse osteoblasts. Endocrinology 1991 129 3139-3146.
36. Nicolas V, Mohan S, Honda Y, Prewett A, Finkelman RD, Baylink DJ & Farley JR. An age-related decrease in the concentration of insulin-like growth factor binding protein-5 in human cortical bone. Calcified Tissue International 1995 57 206-212.
37. Mohan S, Farley JR & Baylink DJ. Age-related changes in IGFBP-4 and IGFBP-5 levels in human serum and bone: implications for bone loss with aging. Progress of Growth Factor Research 1995 6 465-473.
38. Powell DR, Durham SK, Brewer ED, Frane JW, Watkins SL, Hogg RJ & Mohan S. Effects of chronic renal failure and growth hormone on serum levels of insulin-like growth factor-binding protein-4 (IGFBP-4) and IGFBP-5 in children: a report of the Southwest Pediatric Nephrology Study Group. Journal of Clinical Encocrinology and Metabolism 1999 84 596-601.
39. Thoren M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Saaf M, Baylink DJ & Mohan S. Serum levels of insulin-like growth factor binding protein (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy. Journal of Bone and Mineral Research 1998 13 891-899.
40. Ono T, Kanzaki S, Seino Y, Baylink DJ & Mohan S. Growth hormone (GH) treatment of GH-deficient children increases serum levels of insulin-like growth factors (IGFs), IGF-binding protein-3 and -5, and bone alkaline phosphatase isoenzyme. Journal of Clinical Endocrinology and Metabolism 1996 81 2111-2116.
41. Richman C, Baylink DJ, Lang K, Dony C & Mohan S. Recombinant human insulin-like growth factor-binding protein-5 stimulates bone formation parameters in vitro and in vivo. Endocrinology 1999 140 4699-4705.
42. Fryburg DA, Jahn LA, Hill SA, Oliveras DM & Barrett EJ. Insulin and insulin-like growth factor-I enhance human skeletal muscle protein anabolism during hyperaminoacidemia by different mechanisms. Journal of Clinical Investigation 1995 96 1722-1729.
43. Fryburg DA. Insulin-like growth factor I exerts growth hormone- and insulin-like actions on human muscle protein metabolism. American Journal of Physiology 1994 267 E331-E336.
44. de Boer H, Blok GJ & Van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86.
45. Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T & Chihara K. Age-dependent changes in body composition in postmenopausal Japanese women: relationship to growth hormone secretion as well as serum levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3. European Journal of Endocrinology 1998 138 633-639.
46. Rajam S, Baylink DJ & Mohan S. Insulin-like growth factor-binding proteins in serum and other biological fluids: regulation and functions. Endocrine Reviews 1997 18 801-831.